Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competitors from coming into the market, forcing them to overpay for a gastrointestinal drug. Takeda stated the trial had “evidentiary and authorized errors,” and the corporate will enchantment the decision.
The put up Takeda Vows Attraction of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case appeared first on MedCity Information.
